Crossmark

Gonadotropin releasing hormone (GnRH) antagonist administration to decrease the risk of ovarian hyperstimulation syndrome in GNRH agonist cycles triggered with human chorionic gonadotropin

Crossref DOI link: https://doi.org/10.1007/s00404-022-06717-8

Published Online: 2022-08-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mills, Ginevra https://orcid.org/0000-0002-5283-9292
Dahan, Michael H. https://orcid.org/0000-0002-8121-7708
License Information

Text and Data Mining valid from 2022-08-06

Version of Record valid from 2022-08-06
More Information

Article History

Received: 29 May 2022

Accepted: 18 July 2022

First Online: 6 August 2022

Declarations

:

: The authors have no conflicts of interest related to this article. No funding was available for this article.

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of McGill University Health Center # 2019–5129<i>.</i>

: Being a retrospective study, an informed consent waiver was obtained from the director of professional services of the MUHC.

: Being a retrospective study, consent to publish was obtained from the director of professional services of the MUHC.

Document is current

Any future updates will be listed below